Cidara Therapeutics, Inc. (CDTX), a biotechnology company, announced today that it has successfully completed enrollment for its Phase IIb NAVIGATE trial testing CD388, an investigational drug aimed at preventing seasonal influenza.
The trial is being conducted across various clinical sites in the United States and the United Kingdom, involving healthy, unvaccinated adult participants who are not at high risk of influenza complications. The study has successfully reached its target enrollment of 5,000 participants, confirming the company's earlier projections.
Participants in the trial receive a single dose of either 150mg, 300mg, or 450mg of CD388, or a placebo at the onset of the flu season. Researchers will track these individuals throughout the season to identify any cases of influenza that occur despite the administration of the study drug.
In financial markets, CDTX shares are currently trading at $19.15, marking an increase of 8.11%.
